RxDoctor Payments Data

Fernando Holguin, MD

Critical Care Medicine · Aurora, CONPI 1083701775

Payments from drug & device makers

What this record shows

This record is dominated by education: $57 of the $79 with a category attached, or 72.8%. Sanofi-aventis U.S. LLC accounts for 72.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for critical care medicine clinicians in CO, where the typical reported total is $338.

$79in general payments, 2019–2025

Across 2 payments — averaging $39.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$57
  • AstraZeneca$21
$574,258in research payments, 2019–2025

Across 62 payments — averaging $9262.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Insmed, Inc.$403K
  • AstraZeneca$124K
  • Sanofi$23K
  • Astrazeneca AB$9K
  • Astrazeneca UK Limited$8K
  • GSK$7K

What the payments were for

  • Food & beverage$2127%
  • Education$5773%

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC1$57
AstraZeneca1$21

How this compares

$79 in reported general payments places this provider in the 20th percentile of 141 critical care medicine providers in Colorado.

See all critical care medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$19,301
Medicare patients
140
Services billed
277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab84$314,703
Dupixent SyringeDupilumab59$217,995
Trelegy ElliptaFluticasone/Umeclidin/Vilanter138$108,803
Fasenra PenBenralizumab19$106,934
Spiriva RespimatTiotropium Bromide48$44,177
SymbicortBudesonide/Formoterol Fumarate27$15,714
Combivent RespimatIpratropium/Albuterol Sulfate12$10,542
Advair DiskusFluticasone Propion/Salmeterol14$8,368
BreynaBudesonide/Formoterol Fumarate22$6,177
AirsupraAlbuterol Sulfate/Budesonide12$5,426
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,626
Ventolin HfaAlbuterol Sulfate26$2,251
Albuterol Sulfate HfaAlbuterol Sulfate48$1,292
Ipratropium Bromide18$980
Azithromycin37$459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort, Airsupra$21$21,14039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 141 critical care medicine providers in Colorado.

Other critical care medicine in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →